Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by
motor and non-motor symptoms. More than 200 years after its first clinical description, PD …

Covering: 1993 to 2021 (mainly 2017–2021) Alzheimer's and Parkinson's diseases are
neurodegenerative conditions affecting over 50 million people worldwide. Since these …

The aberrant aggregation of proteins is a key molecular event in the development and
progression of a wide range of neurodegenerative disorders. We have shown previously …

This review comprehensively describes the recent advances in the synthesis and
pharmacological evaluation of steroid polyamines squalamine, trodusquemine, ceragenins …

Parkinson's disease (PD) is the second most progressive neurodegenerative disorder of the
central nervous system in the elderly, causing motor impediments and cognitive …

The molecular composition of the plasma membrane plays a key role in mediating the
susceptibility of cells to perturbations induced by toxic molecules. The pharmacological …

Protein tyrosine phosphatase 1B (PTP1B) is an enzyme crucially implicated in aberrations of
various signaling pathways that underlie the development of different human pathologies …

Parkinson's disease (PD) is the second most common neurodegenerative disease in the
world, the first being Alzheimer's disease. Patients with PD have a loss of dopaminergic …

Aggregative α-synuclein and incurring oxidative stress are pivotal cascading events, leading
to dopaminergic (DAergic) neuronal loss and contributing to clinical manifestations of …

Ergothioneine (EGT) is a natural dietary antioxidant derived from certain edible mushrooms,
commonly used as a food additive and supplement, but its effects on Parkinson's Disease …